Related Experiment Videos
[Medullary thyroid carcinomas: persistent hypercalcitoninemia after surgery, reoperations-results]
1Service de chirurgie générale et endocrinienne, clinique chirurgicale Adultes-Est, hôpital Huriez, 1, rue M.-Polonowski, 59037 cedex, Lille, France. c-proye@chru-lille.fr <c-proye@chru-lille.fr>
Annales De Chirurgie
|July 25, 2003
Summary
Persistent hypercalcaemia after medullary thyroid cancer surgery requires careful management. Treatment depends on initial surgery adequacy, focusing on reoperation for inadequate procedures and vigilant monitoring for recurrence in adequate cases.
Area of Science:
- Endocrinology
- Surgical Oncology
- Oncology
Background:
- Persistent hypercalcaemia post-thyroidectomy for medullary thyroid carcinoma (CMT) presents complex management challenges.
- Distinguishing between inadequate initial surgery and locoregional recurrence or systemic disease is crucial.
Purpose of the Study:
- To outline diagnostic and therapeutic strategies for persistent hypercalcaemia after cervicotomy for CMT.
- To clarify indications for reintervention based on surgical adequacy and disease status.
Main Methods:
- Review of management strategies for persistent hypercalcaemia in CMT.
- Emphasis on imaging modalities (including laparoscopy) for staging residual or recurrent disease.
- Correlation of calcitonin levels with prognosis and localization techniques.
Main Results:
- Reoperation with total thyroidectomy and neck dissection is indicated for inadequate initial surgery.
- High suspicion for recurrence is warranted with adequate initial surgery; reintervention must be judicious.
- Calcitonin levels between 50-1000 pg/ml are optimal for localization techniques; systemic disease has a poor prognosis.
Conclusions:
- Prognosis in CMT is determined by local invasion and systemic disease extent, not solely calcitonin levels.
- Future strategies include radio-immunoguided surgery for local disease and radiolabeled immunochemotherapy for systemic disease.